Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women

Journal of Clinical Pathology

Volumn 67, Issue 2, 2014, Pages 153-160

  Esnakula, Ashwini K ^a   Ricks Santi, Luisel ^a   Kwagyan, John ^a   Kanaan, Yasmine M ^a   DeWitty, Robert L ^b   Wilson, Lori L ^b   Gold, Bert ^c   Frederick, Wayne A I ^b   Naab, Tammey J ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOWARD UNIVERSITY HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FASCIN; FORMALDEHYDE; PARAFFIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BASAL LIKE BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY;

EID: 84893073782     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201698     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Amirikia KC, Mills P, Bush J, et al. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 2011;117:2747-53.
3. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502. (Pubitemid 43854964)
4. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-84. (Pubitemid 47257667)
5. Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008;113:608-15.
6. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009;113:357-70.
7. Moran MS, Yang Q, Harris LN, et al. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer 2008;113:2565-74.
8. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol 2010;76:44-52.
9. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 2007;14:2994-3003. (Pubitemid 47460642)
10. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 2007;143:109-18. (Pubitemid 47562451)
11. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012;23(Suppl 6):vi7-12.
12. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, et al. Epithelial- mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008;68:989-97. (Pubitemid 351272216)
13. Katz E, Dubois-Marshall S, Sims AH, et al. An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS ONE 2011;6:e17083.
14. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010;29:6485 -98.
15. Jayo A, Parsons M. Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol 2010;42:1614-17.
16. Li A, Dawson JC, Forero-Vargas M, et al. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol 2010;20:339-45.
17. Grothey A, Hashizume R, Sahin AA, et al. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 2000;83:870-3.
18. Gao X, Wu DH. [Fascin expression in human epithelial tumors and its clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:953-5.
19. Yoder BJ, Tso E, Skacel M, et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005;11:186-92. (Pubitemid 40075794)
20. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006;12:1533-9.
21. Yamamoto Y, Ibusuki M, Nakano M, et al. Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 2009;16:260-7.
22. McCarty KS Jr, Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986;46(8 Suppl):4244s- 8s.
23. Bhargava R, Striebel J, Beriwal S, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009;2:444-55.
24. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes -dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
25. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.
26. Sun J, He H, Xiong Y, et al. Fascin protein is critical for transforming growth factor beta protein-induced invasion and filopodia formation in spindle-shaped tumor cells. J Biol Chem 2011;286:38865-75.
27. Xing P, Li JG, Jin F, et al. Fascin, an actin-bundling protein, promotes breast cancer progression in vitro. Cell Biochem Funct 2011;29:303-10.
28. Al-Alwan M, Olabi S, Ghebeh H, et al. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS ONE 2011;6:e27339.
29. Xue LY, Zou SM, Zheng S, et al. [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic signi ficance]. Zhonghua Zhong Liu Za Zhi 2010;32:838-44.
30. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 2005;37:1787-804. (Pubitemid 40961664)
31. Arjonen A, Kaukonen R, Ivaska J. Filopodia and adhesion in cancer cell motility. Cell Adh Migr 2011;5:421-30.
32. May CD, Sphyris N, Evans KW, et al . Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011;13:202.
33. Guvakova MA, Boettiger D, Adams JC. Induction of fascin spikes in breast cancer cells by activation of the insulin-like growth factor-I receptor. Int J Biochem Cell Biol 2002;34:685-98. (Pubitemid 34270721)
34. Snyder M, Huang XY, Zhang JJ. Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J Biol Chem 2011;286:38886-93.
35. Jansen S, Collins A, Yang C, et al. Mechanism of actin filament bundling by fascin. J Biol Chem 2011;286:30087-96.
36. Chen L, Yang S, Jakoncic J, et al. Migrastatin analogues target fascin to block tumour metastasis. Nature 2010;464:1062-6.